Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2013

01-07-2013 | Original Article

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Authors: Syma Iqbal, Heinz-Josef Lenz, David R. Gandara, Stephen I. Shibata, Susan Groshen, Timothy W. Synold, Edward M. Newman

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2013

Login to get access

Abstract

The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.
Literature
1.
2.
Silvestro L, Anal H, Sommer F (1990) Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum: L-OHP) with CDDP on various cells: correlation with intracellular accumulation. Proc Anticancer Res, pp Abstract # 115
3.
Pendyala L, Kidani Y, Perez R et al (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97:177–184PubMedCrossRef
4.
Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303PubMedCrossRef
5.
Extra JM, Marty M, Brienza S et al (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13–22PubMed
6.
Synold TW, Takimoto CH, Doroshow JH et al (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13:3660–3666PubMedCrossRef
7.
Morgan RJ Jr, Doroshow JH, Synold T et al (2003) Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 9:5896–5901PubMed
8.
Kouroussis C, Agelaki S, Mavroudis D et al (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785–791PubMed
9.
Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim do H, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK (2009) A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol 64(2):347–353. doi:10.​1007/​s00280-008-0878-4
Metadata
Title
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
Authors
Syma Iqbal
Heinz-Josef Lenz
David R. Gandara
Stephen I. Shibata
Susan Groshen
Timothy W. Synold
Edward M. Newman
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2171-4

Other articles of this Issue 1/2013

Cancer Chemotherapy and Pharmacology 1/2013 Go to the issue

Original Article

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

Original Article

Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study

Erratum

Erratum to: Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy

Original Article

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer

Clinical Trial Report

A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder

Original Article

Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits